Date published: 2026-10-8

1-800-457-3801

SCBT Portrait Logo
Seach Input

connexin 37 CRISPR/Cas9 KO Plasmid (h): sc-407258

0.0(0)
Write a reviewAsk a question
Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • connexin 37 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the connexin 37 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    connexin 37 CRISPR/Cas9 KO Plasmid (h)

    sc-407258
    20 µg
    $397.00

    Overview

    GJA4 encodes connexin 37 (Cx37), a gap junction channel protein that assembles into connexons to mediate direct intercellular exchange of ions and small metabolites. Cx37-dependent coupling contributes to vascular homeostasis by coordinating endothelial and smooth muscle cell signaling involved in shear stress responses, proliferation control, and inflammatory signaling. Altered GJA4 expression or channel function has been associated with vascular dysfunction and cardiometabolic traits, and is frequently studied in contexts such as atherosclerosis and thrombosis-related mechanisms. As a component of gap junctional communication, connexin 37 interfaces with broader pathways governing tissue barrier function, cell-cycle regulation, and coordinated multicellular behavior.

    connexin 37 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GJA4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GJA4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GJA4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish connexin 37 protein expression.

    This CRISPR knockout system enables efficient generation of GJA4-deficient cell models for investigation of connexin 37 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting GJA4 exon(s) critical for connexin 37 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple GJA4 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by connexin 37 CRISPR/Cas9 KO Plasmid (h) and connexin 37 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GJA4 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by connexin 37 HDR Plasmid (h) and connexin 37 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GJA4 homology arms to support homology-directed repair at defined GJA4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.